Fluidigm to Participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Nov. 16, 2021 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision...
News
CRISPR Therapeutics and ViaCyte, Inc. to Start Clinical Trial of the First Gene-Edited Cell Replacement Therapy for Treatment of Type 1 Diabetes
-Initiation of patient enrollment expected by year-end--Initiation of patient enrollment expected by year-end- ZUG, Switzerland and CAMBRIDGE, Mass. and SAN...
VistaGen Therapeutics to Present at the Jefferies London Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Nov. 16, 2021 (GLOBE NEWSWIRE) -- VistaGen Therapeutics, Inc. (NASDAQ: VTGN), a biopharmaceutical company committed to...
Oncotelic Announces Successful Completion of the Safety Evaluation of a TGF-β Inhibitor (OT-101) and IL-2 (Aldesleukin) in Phase 1 Combination Trial in Solid Tumor Cancers
AGOURA HILLS, CA, Nov. 16, 2021 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. ("Oncotelic" or the "Company") (OTCQB:OTLC), a leading developer...
Optinose Announces Pricing of Public Offering of Common Stock
YARDLEY, Pa., Nov. 16, 2021 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose...
Abyssinia Biologics Debuts Data on Ultra-sensitive Plasma Immunoassay for Key Synaptotoxin in Alzheimer’s Disease Pathogenesis
Assay developed using Abyssinia proprietary antibodies shows promise as sensitive and specific companion diagnosticFurther pre-clinical data hints at potential therapeutic...
Adventist Health Selects R1 as Patient Billing Partner in its Quest for Consumer Excellence
VisitPay to offer a seamless and complete payment experience for Adventist Health patients expanding the reach of R1’s Entri™ platformMURRAY,...
AGTC Appoints Abraham Scaria, Ph.D., as Chief Science Officer
With 25+ years of experience, Dr. Scaria has led numerous gene therapy programs from early research into clinical development Dr. Scaria...
Coya Therapeutics Announces Successful Completion of Pre-IND Meeting with FDA on COYA101 for the Treatment of Amyotrophic Lateral Sclerosis
Plans to submit an IND to support a Phase 2b clinical trial for COYA101HOUSTON, Nov. 16, 2021 (GLOBE NEWSWIRE) --...
SOTIO Expands its Antibody-Drug Conjugate Pipeline with Exclusive Collaboration and License Agreement with LegoChem Biosciences
SOTIO Biotech licenses LegoChem Biosciences (LCB) technology for five new antibody-drug conjugate (ADC) programsRights to LCB’s ADC platform acquired for...
Erasca to Present at the Evercore ISI 4th Annual HealthCONx Conference
SAN DIEGO, Nov. 16, 2021 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on...
BetterLife Obtains TD-0148A Behavioural Pharmacology Data Confirming its Projected Non-hallucinogenic Property
VANCOUVER, British Columbia, Nov. 16, 2021 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF...
Reflect Scientific Inc. Releases Third Quarter 2021 Financials
OREM, Utah., Nov. 16, 2021 (GLOBE NEWSWIRE) -- Reflect Scientific, Inc. (OTCQB: RSCF), a provider of diverse products and services...
Vaxart Announces Publication of Complete Data from Preclinical COVID-19 Oral Vaccine Hamster Challenge Study in Journal of Infectious Diseases
Study demonstrates oral vaccination significantly reduces viral titers in the lung and protects against COVID-19 in animal modelSOUTH SAN FRANCISCO,...
Daxor Corporation Presents New Data Validating the Benefit of the BVA-100® Blood Test for Optimal Heart Failure Management at Key Scientific Society Meeting
Two New Studies Presented at the American Heart Association Scientific Sessions 2021, Adoption of Technology Reported as “Excellent” and “Valuable”...
Takeda’s Area Offices in Dubai, United Arab Emirates Certified Sustainable and Inaugurated
Takeda Pharmaceuticals Company ("Takeda"), a global, values-based, R&D-driven biopharmaceutical company, hosted the formal inauguration of the company's ICMEA* and Middle...
Report on transactions with ALK-Abelló A/S B-shares and associated securities by managerial staff
ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF): In accordance with article 19 in Regulation (EU) No 596/2014 of...
Quipt Announces Execution of LOI To Acquire Leading Respiratory Supplier With Approximately $13 Million in Annualized Revenue and $1.6 Million in Net Income and Provides Outlook for 2022 Calendar End Run-rate of $180-$190 Million With $38-$43 Million in Adjusted EBITDA
Target Is Located and Services a Major Metro Hub in the Midwestern United States and Would Add Over 15,000 Active...
Abeona Therapeutics Announces Participation at the Jefferies London Healthcare Conference
NEW YORK and CLEVELAND, Nov. 16, 2021 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene...
Mydecine Reports Third Quarter 2021 Financial Results and Provides Business Update
--To Launch Phase 2/3 Smoking Cessation Clinical Trial with Johns Hopkins University (JHU) Signed 5-Year Research Agreement with JHU to...
